Abbisko Therapeutics Co. Ltd. and Allist Pharmaceuticals Co. Ltd. signed an exclusive licensing deal that gives Allist rights to develop, manufacture and commercialize Abbisko’s ABK-3376, an EGFR tyrosine kinase inhibitor for $188 million plus royalties. Read More

Hanall Biopharma Co Ltd.’s batoclimab met the primary and key secondary endpoints in a pivotal phase III trial in generalized myasthenia gravis (gMG) in China, marking the first positive phase III data for the candidate globally. Read More

Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in 2019, Immorna develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA. Read More

Junshi Biosciences Co. Ltd.’s ongericimab, a recombinant humanized anti-PCSK9 monoclonal antibody, met the primary endpoints of reducing the levels of low-density lipoprotein cholesterol in two phase III trials in primary hypercholesterolemia and mixed hyperlipidemia. Read More

Oricell Therapeutics Co. Ltd. raised $45 million in a series B1 round to expand in the U.S. market. RTW Investments LP and the Qatar Investment Authority led the financing, which followed the completion of a $125 million series B round in July 2022. Shanghai-based Oricell plans to use the new funds to support the clinical development of its lead candidates, including Oricar-017, in the U.S. Read More

Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth. Read More

New hires and promotions in the biopharma industry in Asia-Pacific, including: Adagene. Read More

Biopharmas in Asia-Pacific raising money in public or private financings: Akeso, Austrianova, Oricell, SG Austria, Summit. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Amniotics, Atom, Brim, CSL, CSL Behring, Elpiscience, Hutchmed, Innovent, Junshi, JW, Karolinska, SFB Vaccines. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Abbisko, Allist, Amarin, Annji, Atea, Avenue, Biogen Japan, Catalyst, CSL, CSL Seqirus, Eisai, GC, Inspirevax, Landos, Lianbio, Oragenics. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Biophytis, Cstone, Eisai, Genfleet, Mabwell, Priothera, Ractigen, Valeo, Valneva. Read More